Cooper Companies | COO - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 6.8B 1.72B 2026-03
Align Technology USD 1.1B 42.76M 2026-06
AtriCure USD 167.79M 21.62M 2026-06
Bausch Health Companies USD 1.83B 526M 2026-06
Baxter International USD 2.15B 133M 2026-06
Bayer EUR 4.29B 1.44B 2026-06
Becton, Dickinson and Co. USD 708M 105M 2026-06
Boston Scientific USD 539M 914M 2026-06
Cooper Companies USD 124.9M 14.3M 2025-12
Dentsply International USD 239M 49M 2026-06
Dexcom USD 1.1B 13.2M 2026-06
Edwards Lifesciences USD 2.9B 500M 2026-06
Globus Medical USD 507.74M 53.2M 2026-06
Haemonetics USD 223.38M 22.06M 2026-06
Inogen USD 106.48M 2.79M 2025-09
Insulet USD 534.9M 54.5M 2026-06
Integra LifeSciences USD 214.42M 22.39M 2026-06
Intuitive Surgical USD 8.63B 646.3M 2026-06
J&J USD 20.42B 1.27B 2026-06
Medtronic USD 1.15B 135M 2025-12
Merit Medical Systems USD 448.7M 39.38M 2026-06
Novartis USD 6.88B 2.68B 2026-03
ResMed USD 1.47B 191.28M 2026-06
STAAR Surgical USD 148.58M 16.72M 2026-06
Steris USD 482.3M 42.7M 2026-06
Stryker USD 3.39B 513M 2026-06
Tandem Diabetes Care USD 62.82M 116.51M 2026-06
Teleflex USD 300.16M 9.25M 2026-06
Utah Medical Products USD 84.27M 2.09M 2025-09
Zimmer Biomet Holdings USD 410M 14.2M 2026-06